Bioinformatics Articles

  1. The Changing Role Of Computational Mechanics In Drug Discovery 8/3/2026

    Computational models will never replace experimental biology, but their emerging role is different.

  2. Drug Discovery AI Has A Ground Truth Problem 7/27/2026

    If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.

  3. How AI-Powered Automation Is Redefining Pharmaceutical R&D 7/23/2026

    The autonomous lab is not a distant aspiration but a present-day competitive differentiator.

  4. Wondering If Your Org Should Purchase R&D Datasets? 7/1/2026

    Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.

  5. iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody 6/25/2026

    iBio has started clinical trials with a long-acting myostatin/GDF11 antibody that can make weight loss healthier and more durable for patients taking GLP-1 agonists.

  6. Organizing Digital Systems Around Novel Modalities 6/24/2026

    Cell therapies represent an important advancement in our ability to treat difficult cancers, but continued exploration of this new modality will require new digital tools and equipment.

  7. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

    Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.

  8. Advancing Spatial Multiomics for Discovery: From Promise to Practice 6/5/2026

    Spatial multiomics offers extraordinary biological insight, but high costs, tissue bottlenecks, and unclear clinical relevance still limit its reach.

  9. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

    DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

  10. Discovery Dialogues: Stef van Grieken, CEO, Cradle Bio 6/5/2026

    DDO caught up with Stef van Grieken, CEO of Cradle Bio, which uses AI to speed protein design, putting tools in scientists’ hands. Gains in lead optimization are clear, but safety CMC and tough targets remain key challenges.